Biospecimens have been collected at the baseline and the 12-month, 18-month (a limited number of subjects), 24-month, 30-month (a limited number of subjects), 36-month, 48-month, and 72-month follow-up visits and are available upon application.
These biospecimens include serum, plasma, urine, buffy coat (EDTA and citrate), PAXgene tube (one time point at 12 or 48 months) and extracted DNA from baseline. Details of biospecimen collection can be found in the study protocol.
Policies and procedures have been developed for access to these specimens and are posted on the NIAMS website. Interested investigators are encouraged to apply for use of these limited resources.
The Biospecimen Review and Allocation Committee (BRAC) will review submitted proposals and make recommendations to NIAMS regarding allocation and use. Review criteria include significance, approach, innovation, investigator qualifications, plans for data sharing, and research environment, as well as the potential for the proposed research to contribute to the understanding of osteoarthritis or treatment of disease.
Any scientist (U.S. or International) may apply for access to the OAI biospecimens. Investigators must provide proof of funding for proposed analyses prior to gaining access to the biospecimens. Any data generated from the use of these biospecimens must be made accessible to the public through the OAI website and publication of findings.
Completed applications should be submitted as PDF files by email to OAIBiospecimens@kai-research.com. Applications will be reviewed a minimum of three times per year or on a rolling basis.